← Back
$PRME All transactions

Prime Medicine, Inc.

D

$ Value

Shares

45,000

Price

Filed

Aug 5

Insider

Name

Schenkein David P

Title

CIK

0001578200

Roles

Director

Transaction Details

Transaction Date

2025-08-01

Code

D

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. | This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Filing Info

Accession No.

0001894562-25-000050

Form Type

4

Issuer CIK

0001894562

Schenkein David P's History

Date Ticker Type Value
2025-08-01 PRME D
2025-08-01 PRME A
2025-08-01 PRME D
2025-08-01 PRME A
2025-06-04 PRME A $0
2025-06-03 DNLI A $0
2025-06-03 DNLI A $0

Other Insiders at PRME (90d)

Insider Bought Sold Last
Makhni Svetlana Ni
Chief Financial Officer
2026-04-16